- Home
- Advocacy
- Latest News and Practice Data
- CAP opposes gene patent bill, citing harms to health care and innovation
The Senate Judiciary Committee held a hearing on the Patent Eligibility Restoration Act (PERA), which the CAP has warned could hinder health care innovation and patient care.
Senate hearing insights: The October 8 hearing included testimony to address the clarity of patent law, as well as witnesses with differing views on PERA's potential impact on innovation and health care.
- While some support PERA for restoring clarity, the CAP and others warn it could stifle progress and harm patient care by allowing patents on natural phenomena.
- Despite objections from stakeholders, Sens. Thom Tillis (R-NC) and Chris Coons (D-Del.) are intent on moving their bill forward. Sen. Tillis indicated a willingness to address some concerns.
Our advocacy: The CAP has cautioned that PERA would overturn Supreme Court precedent and increase costs for patients by restricting genetic testing capabilities.
- Pathologists can urge lawmakers to oppose PERA by sending a message to Congress from our Action Center.